drugset
drugset / Trial / NCT03870334

Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease

NCT03870334 ↗

Phase 2 Terminated 27 enrolled NImmune Biopharma
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter induction study.

Timeline

Start
2021-05-05
Primary completion
2022-08-26
Completion
2022-08-26

Outcome

Outcome not reported

Stopped: “Decision of Landos Biopharma (not related to safety or efficacy)”

Drugs

EvaluationDrugModalityDoseRoute
Subject omilancor Small molecule 880 mg Oral

Indications

Crohn disease